Skip to main content
main-content

The independent medical news service

30-01-2020 | Oncology | News | Article

Lenvatinib plus pembrolizumab shows promise for RCC and other solid tumors

Phase 1b/2 study data show that combining the multitargeted tyrosine kinase inhibitor lenvatinib with pembrolizumab could be a promising treatment option for patients with advanced renal cell carcinoma and selected other advanced solid tumor types.

13-11-2019 | Oncology | News | Article

HLA-I evolutionary divergence linked to ICI response in cancer

HLA class I evolutionary divergence is associated with response to immune checkpoint inhibitor treatment in people with cancer, show data published in Nature Medicine.

24-09-2019 | Oncology | News | Article

Inflammatory arthritis persists post immune checkpoint inhibitor therapy

Immune checkpoint inhibitor-induced inflammatory arthritis among patients with cancer may need long-term management by rheumatologists after cessation of treatment, but does not appear to affect cancer outcomes, say researchers.

12-08-2019 | Oncology | News | Article

Individuals with autoimmune disease ‘good candidates’ for cancer immunotherapy

A French database analysis lends further support for the use immune checkpoint inhibitors for cancer in patients with pre-existing autoimmune disease.

31-07-2019 | Oncology | News | Article

Durable survival with nivolumab in patients with advanced RCC, NSCLC

Five-year data from the phase I CA209-003 trial indicate that the PD-1 inhibitor nivolumab is associated with long-term survival benefits among heavily pretreated patients with advanced renal cell carcinoma or non-small-cell lung cancer.

28-06-2019 | Oncology | News | Article

Checkpoint inhibitor rechallenge feasible after irAE-related discontinuation

Two studies point to the feasibility of resuming immune checkpoint inhibitors in patients who discontinue treatment due to immune-related adverse events.

Image Credits